| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Opus Genetics, Inc. | SVP of Corp. Dev. | Common Stock | 185,446 | $213,263 | $1.15 | 13 Mar 2025 | Direct |
| Opus Genetics, Inc. | SVP of Corp. Dev. | Employee Stock Option (right to buy) | 29,500 | 13 Mar 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| IRD | Opus Genetics, Inc. | 13 Mar 2025 | 2 | $0 | 4 | SVP of Corp. Dev. | 17 Mar 2025, 20:49 |
| IRD | Opus Genetics, Inc. | 04 Feb 2025 | 1 | -$7,696 | 4 | SVP of Corp. Dev. | 06 Feb 2025, 16:35 |
| IRD | Ocuphire Pharma, Inc. | 18 Jan 2024 | 2 | $0 | 4 | SVP of Corp. Dev. | 22 Jan 2024, 18:01 |
| IRD | Ocuphire Pharma, Inc. | 10 Jan 2024 | 1 | -$13,161 | 4 | SVP of Corp. Dev. | 12 Jan 2024, 16:17 |
| IRD | Ocuphire Pharma, Inc. | 10 Jan 2023 | 2 | $0 | 4 | SVP of Corp. Dev. & Ops & Sec. | 12 Jan 2023, 16:33 |
| IRD | Ocuphire Pharma, Inc. | 28 Jan 2022 | 1 | $0 | 4 | VP of Corp. Dev. & Ops & Sec. | 01 Feb 2022, 15:29 |